GILD Jun 2024 42.500 put
| Previous Close | 0.0800 |
| Open | 0.0200 |
| Bid | 0.0000 |
| Ask | 0.0400 |
| Strike | 42.50 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.0200 - 0.0200 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 70 |
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
ACCESSWIREGilead's FOCUS Program Helps Zero In on Early HIV Detection
NORTHAMPTON, MA / ACCESSWIRE / May 9, 2024 / A 22-year-old college student who didn't feel well was treated at an urgent care facility in Baton Rouge, Louisiana and expected to recover soon. But when his symptoms worsened, he returned to the emergency ...
